
With the Dividend Data connector, your AI app answers from the same data as this page and links the page behind each number. A free Dividend Data account connects.
Questions to try
MRNA does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for MRNA and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses here and all seven in the Value Graph.
TapClick below to see what's inside, then upgrade to unlock for MRNA and 80,000+ other tickers.
The latest quarter of all 4 metrics Moderna, Inc. reports, from its segment revenue to its operating figures, each with its change from the quarter before and from a year earlier, and its history back to Dec 2019.
TapClick below to see what's inside, then upgrade to unlock it for MRNA and every other company we cover.
4 suppliers and 4 customers of Moderna, Inc., named in SEC filings, company releases and earnings calls, with the quote behind each one, the share of revenue where a filing gives it, and how it moved.
TapClick below to see what's inside, then upgrade to unlock it for MRNA and every other company we cover.
See exactly how MRNA's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MRNA and 80,000+ other tickers.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and…

Moderna's revenue guidance for 2026 falls short of analyst targets, meaning a sales miss may be coming. Moderna's earnings might surprise to the upside if its cost-cutting pays off.

The biotech plans to reinvest in its pipeline, particularly oncology treatments like its personalized cancer vaccine.

71 West Capital Partners bought a new stake in shares of Moderna, Inc. (NASDAQ: MRNA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 2,563 shares of the company's stock, valued at approximately $494,000. Other institutional investors and hedge funds have also

Moderna's revenue came in better than expected last quarter, and the company raised its guidance. Nearly all of its revenue comes from COVID-related products.

MRNA targets a year-end 2026 FDA filing for its personalized cancer therapy, intismeran, potentially paving the way for a regulatory decision in 2027.